Nuvalent (NUVL) EBT (2020 - 2026)
Nuvalent (NUVL) reported EBT of -$109.1 million for Q1 2026, down 29.24% on a YoY basis from -$154.2 million in Q1 2025, and up 7.97% quarter-over-quarter from -$118.6 million in Q4 2025.
Nuvalent (NUVL) EBT (2020 - 2026) Analysis & Trends
Nuvalent has reported EBT for 7 years, with the latest figure at -$109.1 million in Q1 2026.
- For the quarter ending Q1 2026, EBT fell 29.24% year-over-year to -$109.1 million; the trailing twelve-month figure through Mar 2026 stood at -$449.5 million (down 49.67% YoY), and the FY2025 full-year result was -$424.8 million, down 63.39% from the prior year.
- EBT for Q1 2026 stood at -$109.1 million, up from -$118.6 million in the prior quarter.
- The five-year high for EBT was -$17.5 million in Q1 2022, with the low at -$122.3 million in Q3 2025.
- Historically, EBT has averaged -$58.9 million across 5 years, with a median of -$44.1 million in 2024.
- Annual changes were most pronounced in 2022 — EBT plunged 184.79% — and 2026, when it slipped 29.24%.
- Nuvalent's EBT stood at -$26.1 million in 2022, then slumped by 46.62% to -$38.3 million in 2023, then tumbled by 94.8% to -$74.6 million in 2024, then plunged by 58.94% to -$118.6 million in 2025, then climbed by 7.97% to -$109.1 million in 2026.
- The last three EBT figures came in at -$109.1 million (Q1 2026), -$118.6 million (Q4 2025), and -$122.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 19.60 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -15.31 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | -3.18 Mn |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.25 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -56.48 Mn |
| 10 | Nuvalent | 9.69 Bn | 9.69 Bn | - | -109.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -109.11 Mn |
| Dec 31, 2025 | -118.55 Mn |
| Sep 30, 2025 | -122.31 Mn |
| Jun 30, 2025 | -99.51 Mn |
| Mar 31, 2025 | -84.43 Mn |
| Dec 31, 2024 | -74.59 Mn |
| Sep 30, 2024 | -84.31 Mn |
| Jun 30, 2024 | -57.00 Mn |
| Mar 31, 2024 | -44.10 Mn |
| Dec 31, 2023 | -38.29 Mn |
| Sep 30, 2023 | -33.65 Mn |
| Jun 30, 2023 | -29.09 Mn |
| Mar 31, 2023 | -25.19 Mn |
| Dec 31, 2022 | -26.12 Mn |
| Sep 30, 2022 | -19.72 Mn |
| Jun 30, 2022 | -18.47 Mn |
| Mar 31, 2022 | -17.55 Mn |
| Dec 31, 2021 | -17.38 Mn |
| Sep 30, 2021 | -12.43 Mn |
| Jun 30, 2021 | -9.85 Mn |